The documents linked below provide examples of companies disclosing information related to drug R&D costs to the U.S. Securities and Exchange Commission (SEC). These documents are in the Google’s cloud-based Docs program. You can view and/or download them (no Google… Continue Reading
On April 29, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading
In an order dated April 11, 2019, Judge Peter J. Messitte granted the NIH’s motion to dismiss for lack of jurisdiction in the lawsuit filed by KEI, which appealed an NIH decision to grant an exclusive license on a CAR… Continue Reading
For a general timeline of the Bayh-Dole Act, see this page. 1980. December 12. The Bayh-Dole Act was enacted into law as part of Public Law 96-517, including Section 203 that provide march-in rights. 1984. November 8. The Bayh-Dole statute was… Continue Reading
KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading
On January 7, 2019, KEI and MSF (Doctors Without Borders/Médecins Sans Frontières USA) submitted comments to the Federal Register notice (83 FR 65696) on the “Prospective Grant of Exclusive Patent License: Production of Live Respiratory Syncytial Virus and Parainfluenza Virus… Continue Reading
On Monday January 7, 2019, KEI submitted joint comments on behalf of Health GAP, Social Security Works, the Union for Affordable Cancer Treatment, and Professor Brook Baker of Northeastern University to the Federal Register notice (83 FR 65694) for the”Prospective… Continue Reading
Jaime M. Greene Senior Licensing and Patenting Manager NCI Technology Transfer Center Email: greenejaime@mail.nih.gov December 16, 2018 Re: Comments on “Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use for certain inventions” (83 FR 61659) Dear… Continue Reading
The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading
In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading